Latest News

Stay up to date with the latest stock market news from around the world. From breaking news written by our finance analysts to event-driven market news on a global scale.

SWX:HOLN
SWX:HOLNBasic Materials

Holcim (SWX:HOLN) Valuation Check After Fossil Free Cement Breakthrough With Fully Electrified Clinker Production

Holcim (SWX:HOLN) is back in focus after partner SaltX Technology produced Portland-quality cement clinker using a fully electrified process, confirming a proof of concept for fossil-free cement production ahead of a planned pilot plant. See our latest analysis for Holcim. Holcim's latest electrification breakthrough comes as the stock trades at CHF74.1, with a 10.27% 1 month share price return but a 5.17% year to date share price decline. The 5 year total shareholder return of 216.06% points...
NYSE:PMT
NYSE:PMTMortgage REITs

PennyMac Mortgage Investment Trust (PMT) Q1 Revenue Slowdown Tests Bullish Scale Narrative

PennyMac Mortgage Investment Trust (PMT) opened 2026 with Q1 total revenue of US$82.1 million and basic EPS of US$0.16, setting a quieter tone after a stronger run through 2025. Over the last year, the stock has seen quarterly revenue range from US$145.3 million to US$215.6 million and basic EPS swing between a small loss of US$0.04 and a high of US$0.55, while trailing twelve month EPS reached US$1.16 on revenue of US$758.8 million. Taken together, the latest figures point to a period where...
NYSE:DE
NYSE:DEMachinery

A Look At Deere (DE) Valuation As Brent Norwood Takes Over As Chief Financial Officer

Why Deere’s new CFO matters for shareholders Deere (DE) just reshaped its finance leadership, elevating Brent Norwood to senior vice president and chief financial officer on May 1, a move drawing attention ahead of the May 21 earnings report. For you as an investor, this kind of transition sits at the intersection of corporate oversight and capital allocation, two areas that can influence how consistently a company funds growth projects, manages its balance sheet, and returns cash to...
NasdaqGM:URGN
NasdaqGM:URGNBiotechs

UroGen Pharma (URGN) Q1 Revenue Surge Tests Bearish Cash Runway Concerns

UroGen Pharma (URGN) opened 2026 with Q1 revenue of US$51.0 million and a basic EPS loss of US$0.47, alongside a net income loss of US$23.6 million, setting a clear marker for how the business is scaling while remaining loss making. The company has seen quarterly revenue move from US$20.3 million in Q1 2025 to US$51.0 million in Q1 2026, while basic EPS over that span ranged from a loss of US$1.05 in Q2 2025 to a loss of US$0.47 in the latest quarter. As a result, investors are getting a...
NasdaqGS:RXRX
NasdaqGS:RXRXBiotechs

Recursion Pharmaceuticals (RXRX) Q1 Loss Of US$117.5 Million Tests AI Growth Narrative

Q1 2026 results snapshot Recursion Pharmaceuticals (RXRX) has kicked off Q1 2026 with revenue of US$6.5 million, basic EPS of US$0.22 loss, and trailing twelve month revenue of US$66.4 million against a trailing net loss of US$559.8 million. Over recent quarters, the company has seen revenue move between US$4.5 million and US$35.5 million, while quarterly basic EPS has ranged from a loss of US$0.20 to a loss of US$0.53 as the business continues to invest heavily and run at sizable losses,...
NasdaqGS:SLDP
NasdaqGS:SLDPAuto Components

Solid Power (SLDP) Q1 Loss Narrows To US$0.06 EPS Challenging Bearish Narratives

Solid Power (SLDP) has released its Q1 2026 numbers, with revenue at US$2.1 million and a basic EPS loss of US$0.06, setting the stage for another quarter where the income statement is firmly in the red. The company has seen quarterly revenue move from US$6.0 million in Q1 2025 to US$2.1 million in Q1 2026, while basic EPS has shifted from a loss of US$0.08 to a loss of US$0.06 over the same period, giving investors a mixed read on the top line and per share performance. With consensus still...
NYSE:LOMA
NYSE:LOMABasic Materials

Loma Negra (NYSE:LOMA) Q1 EPS Rebound Tests Bearish Margin Compression Narrative

Loma Negra Compañía Industrial Argentina Sociedad Anónima (NYSE:LOMA) opened 2026 with Q1 results that put revenue at about ARS 218.7b and basic EPS at ARS 351.37, setting a clear marker for how the year is starting to shape up. Over the past few quarters, the company has seen revenue move from about ARS 279.4b in Q4 2024 to ARS 172.9b in Q1 2025 and then to ARS 270.6b in Q4 2025. Basic EPS shifted from ARS 360.89 to ARS 195.07 and then to ARS 64.39, so this latest print lands against a...
NasdaqGS:BCRX
NasdaqGS:BCRXBiotechs

BioCryst Pharmaceuticals (BCRX) Quarterly Loss Of US$721.8m Challenges Bullish Earnings Narratives

BioCryst Pharmaceuticals (BCRX) opened 2026 with Q1 revenue of US$156.4 million and a basic EPS loss of US$2.98, compared with Q1 2025 revenue of US$145.5 million and essentially breakeven EPS of US$0.00. Over the same period, trailing 12 month EPS shifted from a profit of US$1.26 to a loss of US$2.10. Over the past year, revenue on a trailing 12 month basis moved from US$503.5 million to US$885.7 million, while net income moved from a profit of US$263.9 million in 2025 Q4 to a loss of...